Correspondence  by unknown
effect of age and gender on time-domain HRV and HR, at
least in the young and middle-aged. If the authors had
included a sufficient number of participants (at least 20
healthy subjects per decade and per gender), this article
indeed could have delineated the effects of age and gender
on time-domain HRV and would have forwarded normal
ranges of HRV and HR over nine decades. Unfortunately,
only their most important study limitation can be empha-
sized: Additional larger studies that include the underrep-
resented groups are needed.
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REPLY
We appreciate the interest of Drs. Ramaekers, Ector, and
Aubert in our recent report on age and gender effects on
heart rate variability (HRV) and heart rate (HR) (1) and
have reexamined our data with respect to the questions
posed. Unfortunately, the authors did not provide a sum-
mary of their own data (2), on which they seem to largely
base their comments. This detracts from meaningful com-
parisons with their data.
Insofar as the questions posed are concerned, please
consider the following. A number of the issues also are
discussed in the limitations section of the article.
1. Raemakers et al. stated that statistical analysis should
have been preceded by a log transformation. We agree
that a transformation should be carried out in instances
where data are skewed. However, we compared limited
10 year age-range groups and found that data for 6 of the
8 age groups were normally distributed, even using the
pNN50 measure. Therefore, we felt justified in not
subjecting the data to log transformation before analysis.
2. We agree that the relatively small number of subjects in
the oldest age groups, particularly men over age 70,
represents a limitation of the study and that caution is
indicated in interpreting the decrease in HRV in this
group of subjects. However, to our best knowledge, this
is the largest published HRV data set to date for healthy
individuals over age 70. We are currently collecting data
from additional subjects over age 70, but it may be
difficult to achieve equal numbers of healthy older men
and women due to gender differences in mortality.
3. We agree with Raemakers et al. that a larger sample size
would be helpful in delineating the physiologic mecha-
nisms underlying age related gender HRV differences
and state this in our article. Larger sample size also
would permit a decade-by-decade analysis. Suggestions
that power spectrum analysis may be important with
respect to mechanistic determinations would be more
relevant if power spectral bands associated with sympa-
thetic activity were well defined.
More specifically, in our study, gender effects on HRV
were measure dependent. As shown in scatter plots of
HRV data from our total sample (Figure 2 B and C) (1)
HRV determined using rMSSD and pNN50 decreases
markedly with aging before age 50. Using these mea-
sures, HRV of young women is lower than that of age
matched men, with gender differences disappearing after
age 30. Parasympathetic modulation of heart rate (HR)
also decreases with aging (to age 30) (3). Using SDNN,
SDANN, and SDNN index measures, gender differences
disappear after age 50. Findings that HRV of women
determined using pNN50 and rMSSD, which reflect
parasympathetic activity, is lower than in age matched
men, suggest that gender HRV differences, at least
before age 30, may reflect differences in parasympathetic
modulation.
4. We agree that the lesser age dependence of SDNN and
SDANN measures may be largely due to the lesser age
dependence of SDNN and SDANN in females.
5. As mentioned by Ramaekers et al. (2) and others (4), HR
is a major determinant of HRV. Circadian changes also
represent an important consideration. However, in this
report, we did not consider these because it would have
made the report too long and complex. In addition, to
our best understanding, there are no established methods
for correcting HRV for mean HR. Tsuji et al. (4)
reported aging and HR effects on HRV separately.
In conclusion, we again thank Dr. Ramaekers and his
colleagues for their comments. However, we believe that
despite the limitations, our study has important implications
to our understanding HRV of normal individuals over the
life span and to the predictive use of HRV with respect to
mortality and cardiovascular morbidity, particularly in older
individuals.
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Cost-effectiveness of an Ineffective Therapy(?)
In the June issue of the Journal, Pedretti et al. (1) presented
an innovative study on the cost-effectiveness of different
tests to select postinfarct patients for amiodarone therapy.
However, as the accompanying editorial (2) pointed out, the
“cost-effectiveness of these tests can be no better than the
cost-effectiveness of the therapies prescribed based on their
results.” To this end, I think the conclusion reached in this
paper is weak and may be misleading for readers of this
journal.
Amiodarone has not been shown to improve overall
survival in post-MI patients. Only a meta-analysis (3),
which has important limitations, suggests a possible benefit.
The analyses in the present study relied entirely on the data
from EMIAT and CAMIAT trials, which did not show an
overall improvement in survival. No tests can be cost-
effective if the treatment selected is not. Using amiodarone
as a sole therapy in this high-risk group of patients,
especially those with a positive EP study, is clinically
unrealistic and renders the accompanying analyses irrele-
vant.
On the other hand, implantable defibrillators (ICDs)
have been shown to improve overall survival in two pub-
lished (MADIT and AVID) (4,5) and two unpublished
(CIDS and CASH) prospective randomized controlled
trials. Unfortunately, the use of ICDs as an alternative to
amiodarone was not emphasized by Pedretti et al. (1) or in
the accompanying editorial (2). Had the authors included
this proven therapy as a treatment option in their study,
invasive strategy with EP studies may turn out to be
cost-effective simply because of the effectiveness of ICD and
its superiority over amiodarone (4,5).
The conclusions reached by Pedretti et al. (1) at best
provide little clinically useful information and at worst are
potentially misleading. Because an inferior treatment was
chosen for analysis, it is not surprising that invasive electro-
physiology studies did not prove to be cost-effective. By
omitting to include ICDs as a treatment option and by
failing to discuss this important limitation, this study does
the readers of this journal a disservice by undermining the
true utility of electrophysiology studies in selecting patients
for appropriate treatment (4). I believe that the publication
of this paper, sets us back a full decade in our practice of
clinical electrophysiology.
James J. C. Ong, MD, FACC, FCCP
Tarzan, California
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REPLY
Dr Ong expressed some criticism concerning our recent
paper (1).
Results of base-case analysis showed that amiodarone
improved survival in recent post-MI patients with low heart
rate variability at an incremental cost between $20,000 and
$40,000/additional QALY which is consistent with other
currently founded programs, such as hemodialysis or treat-
ment of mild hypertension with diuretic drugs or propran-
olol. In our model, this acceptable incremental cost-
effectiveness ratio derived from a 17% amiodarone-induced
reduction in total mortality at two years, which is similar to
the significant survival benefit observed in a recent pub-
lished meta-analysis (2). Sensitivity analysis showed similar
cost-effectiveness ratios in other subgroups of patients
selected by different noninvasive testing, but not in those
with CAMIAT and EMIAT screening criteria. These data
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